Evaluation of Varenicline Safety, Tolerability, Pharmacokinetics and Pro-Cognitive Effects in Healthy Elderly Non-Smoking Subjects

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy, Non-Smoking

In brief

1. Characterize the tolerability and safety of repeated doses of varenicline in healthy non-smoking elderly subjects. 2. Describe the steady state pharmacokinetics of varenicline in healthy non-smoking elderly subjects. 3. Evaluate the potential effects of repeat doses of varenicline on cognition in healtly non-smoking elderly subjects.

Key facts

Study ID

NCT00694044

Run by

Pfizer

People needed

50

Starts

2008-04-01

Expected to finish

2008-06-01

Last updated by the study team

2009-06-02

Who can join

Age: 65 and older, up to 85. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy, Elderly (65-85 years inclusive), Non-smoker

You may not qualify if…

• Creatinine Clearnace < 30 ml/min, Evidence or history of clinically significant, unstable diseases

Where it is running

• Pfizer Investigational Site — Miami, Florida, United States
• Pfizer Investigational Site — Orlando, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.